Summary
Veeva Systems closed fiscal 2023 with fourth-quarter revenue of $563.4 million, up 16% from $485.5 million in the prior-year quarter. Full-year revenue was $2,155.1 million, up 16% from $1,850.8 million. Subscription services did the heavy lifting, with fourth-quarter subscription revenue of $460.2 million, up 16%, and full-year subscription revenue of $1,733.0 million, up 17%. Subscription services accounted for 80% of total revenue for the fiscal year. The company ended the year with 1,388 customers, an increase of 174 from the year prior.
Growth tilted toward clinical software. R&D Solutions subscription revenue reached $217.3 million in the quarter, against $168.4 million a year earlier, while Commercial Solutions subscription revenue was $242.9 million, against $227.3 million. Veeva signed three additional top 20 pharmaceutical companies for its Vault EDC product in the quarter, bringing the total committed to using it for all new clinical trials to six. Management pointed to more than 30 major software and data products and to broad-based growth across customer segments and geographies.
Profitability was mixed. Fourth-quarter operating income fell 9% to $108.9 million from $119.7 million a year earlier. Gross profit for the quarter was $399.1 million, up 14.1%, yet gross margin slipped to 70.8% from 72.0%. Operating margin dropped to 19.3% from 24.7%. For the full fiscal year, operating income of $459.1 million was down 9.2% from $505.5 million, and operating margin of 21.3% fell from 27.3%. Stock-based compensation explains much of the gap: it was $95.5 million in the quarter, compared with $61.7 million a year earlier. Research and development expense climbed 36% for the fiscal year to $520.3 million as headcount grew.
Net income moved the other way. Fourth-quarter net income rose 94% to $188.5 million from $97.1 million, and full-year net income was $487.7 million, up 14.1% from $427.4 million. Full-year diluted earnings per share came in at $3.00, against $2.63. Taxes did much of the work. The full-year effective tax rate was 4.2% versus 16.6%, and excess tax benefits from stock plans reached $94 million, up from $56 million, largely because the chief executive exercised stock options.
Cash flow held steady. Operating cash flow was $63.4 million in the quarter, up 17.3% from $54.1 million, and $780.5 million for the fiscal year, up 2.1% from $764.5 million. Deferred revenue ended the year at $869.3 million, up 18.8% from $731.7 million. Cash, cash equivalents, and short-term investments totaled $3.1 billion at January 31, 2023.
Guidance points to slower growth ahead. For the fiscal first quarter ending April 30, 2023, Veeva guides to non-GAAP operating income of $141 million to $143 million and non-GAAP diluted earnings per share of $0.79 to $0.80. For the full fiscal year ending January 31, 2024, it guides to non-GAAP operating income of about $800 million and non-GAAP diluted earnings per share of approximately $4.33. For the fiscal year ending January 31, 2025, management targets non-GAAP operating income of at least $1,000 million. Management also said total revenue growth for the fiscal year ending January 31, 2024 is expected to decline compared with the prior fiscal year.
Several items complicate the story. Starting February 1, 2023, the master subscription agreements that govern multi-year orders generally include a termination for convenience right, which changes the timing of revenue recognition and will have an adverse impact on revenue in fiscal 2024. Veeva is also adding an annual inflation adjustment capped at the lower of 4% or the Consumer Price Index. It still expects life sciences companies to reduce sales representatives through fiscal 2024, which could weigh on Veeva CRM and other Commercial Solutions. The requirement to capitalize and amortize research and development expenditures is expected to cut operating cash flow by roughly $90 million in fiscal 2024. General and administrative expense also absorbed higher third-party fees tied to ongoing litigation.
Forecast
Reported figures
GAAP, from SEC filings| Metric | Q4 FY2023 | Q3 FY2023 | QoQ | Q4 FY2022 | YoY |
|---|---|---|---|---|---|
| Revenue | $563.4M | $552.4M | +2.0% | $485.5M | +16.0% |
| Gross profit | $399.1M | $398.4M | +0.2% | $349.6M | +14.1% |
| Gross margin | 70.8% | 72.1% | -1.3 pp | 72.0% | -1.2 pp |
| Research & development | $142.5M | $130.3M | +9.4% | $105.3M | +35.4% |
| Sales & marketing | $89.0M | $93.9M | -5.2% | $79.2M | +12.4% |
| General & administrative | $58.6M | $52.9M | +10.8% | $45.4M | +29.0% |
| Total operating expenses | $290.2M | $277.0M | +4.7% | $229.9M | +26.2% |
| Operating income (loss) | $108.9M | $121.4M | -10.3% | $119.7M | -9.0% |
| Operating margin | 19.3% | 22.0% | -2.7 pp | 24.7% | -5.3 pp |
| Net income (loss) | $188.5M | $108.5M | +73.8% | $97.1M | +94.2% |
| Net margin | 33.5% | 19.6% | +13.8 pp | 20.0% | +13.5 pp |
| Diluted EPS | $1.16 | $0.67 | +$0.49 | $0.60 | +$0.56 |
| Customers | 1,388 | 861 | +61.2% | — | — |
Risks
Veeva announced plans to migrate its multichannel CRM applications from the Salesforce platform to Veeva Vault and does not intend to renew its Salesforce agreement. All existing CRM customers must migrate by September 1, 2030, and migration disruptions or customers choosing competing CRM providers could materially and adversely affect operating results.
Since February 1, 2023, master subscription agreements governing multi-year orders generally include a termination for convenience right. MD&A states this changes revenue recognition timing and will adversely impact revenue for the fiscal year ending January 31, 2024, and expects gross margin and operating margin to decrease.
Inflationary pressures, rising interest rates, volatility in the financial sector including the failure of Silicon Valley Bank, recession concerns, and the Russian invasion of Ukraine may disrupt life sciences industry spending. Reduced funding for early-stage life sciences companies resulted in reduced sales and adversely affected financial results for FY2023 and may continue.
Nearly all revenues are from life sciences customers, exposing Veeva to drug pricing reforms such as the Inflation Reduction Act, industry consolidation, funding reductions, and changes in sales and marketing practices. MD&A notes expected additional sales representative reductions through FY2024 could negatively impact Veeva CRM and other Commercial Solutions.
Third-party data providers, particularly IQVIA, restrict customers from uploading healthcare professional and healthcare organization data into Veeva Network Customer Master and have restricted Veeva Nitro and new data types such as real world data and genomics. These restrictions have harmed sales and adoption and may continue.
R&D expenses increased 36%, sales and marketing increased 21%, and general and administrative increased 27% for FY2023, partly due to higher employee compensation and stock-based compensation. MD&A expects operating expenses and stock-based compensation to increase in FY2024 and operating margin to decrease.
Top 10 customers accounted for 29% of total revenues in FY2023, down from 31% in FY2022 and 36% in FY2021. Loss or non-renewal of key customers could slow revenue growth or cause revenues to decline.
Sales cycles may span 12 months or longer, and since the quarter ended July 31, 2022 Veeva has experienced increased project scrutiny for certain potential projects. Lengthened sales cycles or unsuccessful sales investments would harm operating results and growth.
Competition for highly skilled employees is intense, and higher global compensation increases in the fiscal quarter ended April 30, 2022 increased expenses. If equity award values decline or compensation changes are negatively received, Veeva may face attrition or recruiting difficulty.
Veeva is defending active litigation with IQVIA and Medidata, including IQVIA trade secret misappropriation claims since January 2017. G&A expenses for FY2023 included an $11 million increase in professional services primarily for ongoing litigation, and IP claims could require damages or restrict offerings.
The Tax Cuts and Jobs Act requirement to capitalize and amortize R&D expenditures reduced FY2023 cash from operations and is expected to reduce operating cash flow by approximately $90 million in the fiscal year ending January 31, 2024 if not modified.
Veeva faces competition from IQVIA, Dassault Systemes, Oracle, and others, and some competitors have greater resources. Competitors may offer price concessions or delayed payment terms in the recent macroeconomic environment, which could pressure revenues and margins.
Veeva has limited experience selling newer offerings such as Veeva Compass for longitudinal patient data and MyVeeva for Patients. If these newer solutions are not successfully adopted, the growth rate of revenues and operating results will be adversely affected.
MD&A states that growth rates of total revenues and subscription services revenues for the fiscal year ending January 31, 2024 are expected to decline compared to the prior fiscal year. This follows FY2023 total revenue growth of 16% and subscription services revenue growth of 17%.
SaaS KPIs
All quarters →Total Customers
Non-GAAP Operating Margin
Commercial Solutions customers
R&D Solutions customers
Non-GAAP subscription services gross margin
Summary, forecast, risks and KPIs are extracted from VEEVA SYSTEMS INC's SEC filings for Q4 FY2023 (10-Q / 10-K and the 8-K earnings release); GAAP figures in the summary are checked against the reported XBRL data. They can contain errors; the filings are authoritative. Processed Oct 6, 2026.